Epsilon Health
Work Here?
Overview
About Epsilon Health
Simplify's Rating
Why Epsilon Health is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Healthcare
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Simplify's Take
What believers are saying
- June 2026 receipts reached A$3.66 million, up 72% year over year.
- July 2026 cash rose to A$1.47 million with positive operating cash flow.
- Puro New Zealand could add about A$2 million revenue in 2026 and more Europe work.
What critics are saying
- Auditor A D Danieli flagged going-concern doubt in November 2025.
- Epsilon still relies on related-party funding from Peter Giannopoulos and Lekarna through 2027.
- The 2023-2026 Josh Cui dispute shows governance fragility and litigation overhang.
What makes Epsilon Health unique
- Epsilon Healthcare’s integrated model spans CDMO, clinics, and pharmacy operations across Australia.
- The February 2026 Puro New Zealand deal gives Epsilon Pharma export manufacturing relevance.
- Renewed manufacturing permits and a new Newtown pharmacy deepen clinical-to-dispensing workflow.
Help us improve and share your feedback! Did you find this helpful?
Epsilon Health is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →
About Epsilon Health
Simplify's Rating
Why Epsilon Health is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Healthcare
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Epsilon Health is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →